CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials
July 19, 2021 16:41 ET
|
CytoDyn Inc.
VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis
July 19, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b
July 12, 2021 06:00 ET
|
CytoDyn Inc.
CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks VANCOUVER, Washington, July 12, 2021 (GLOBE...
CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab
July 06, 2021 06:00 ET
|
CytoDyn Inc.
VANCOUVER, Washington, July 06, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV
July 01, 2021 18:07 ET
|
CytoDyn Inc.
Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications VANCOUVER,...
CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms
June 21, 2021 08:30 ET
|
CytoDyn Inc.
VANCOUVER, Washington, June 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments
June 16, 2021 16:01 ET
|
CytoDyn Inc.
VANCOUVER, Washington, June 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
Nature Communications Publishes Study of CytoDyn’s Leronlimab Preventing HIV Infection in Primates
June 07, 2021 08:51 ET
|
CytoDyn Inc.
Leronlimab to be studied as potential HIV PrEP drug in humans through an early clinical trial VANCOUVER, Washington, June 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or...
CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19
June 01, 2021 09:23 ET
|
CytoDyn Inc.
VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR5...
CytoDyn Receives First Purchase Order from Chiral Pharma Corporation for Use of Leronlimab Under CSP for COVID-19 Patients in the Philippines
June 01, 2021 09:15 ET
|
CytoDyn Inc.
Chiral is simultaneously working on application for Emergency Use Authorization VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a...